Phaseline

Companies › Minghui Pharmaceutical (Hangzhou)

Minghui Pharmaceutical (Hangzhou): clinical trials, targets and expected readouts

10 active drug programs in 19 registered trials: 11 Phase 1, 6 Phase 3, 2 Phase 2; Oncology, Ophthalmology, Immunology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MHB018A
Humanized anti-IGF1R antibody
IGF1RPhase 3Thyroid Associated Ophthalmopathies; Thyroid Eye Disease (TED); Thyroid Eye Disease, TEDDec 2026
MH004 1.0% Ointment–Phase 3VitiligoFeb 2028
MHB036C for Injection
antibody-drug conjugate
–Phase 2Advanced Breast Cancer; Advanced Solid Tumor; Advanced Lung CancerApr 2027
MHB039A for Injection
bispecific antibody
–Phase 2Advanced Breast Cancer; Advanced Solid Tumor; Advanced Lung Cancer; Advanced Malignant Solid TumorApr 2028
MHB009C–Phase 1Advanced Malignant Solid TumorFeb 2028
MHB118C for Injection–Phase 1Advanced Malignant Solid TumorMar 2029
MHB046C–Phase 1Advanced Solid CancerMay 2029
MHB088C–Phase 1Advanced Malignant Solid TumorAug 2029
MHB042C–Phase 1Advanced Malignant Solid TumorOct 2029
MHB048C–Phase 1mCRPC (Metastatic Castration-resistant Prostate Cancer)Oct 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06989918MHB018APhase 3Thyroid Associated OphthalmopathiesOphthalmologyDec 2026
NCT06373406MHB036C for InjectionPhase 1Advanced Solid TumorOncologyApr 2027
NCT07257185MHB018APhase 3Thyroid Eye Disease (TED)OphthalmologyAug 2027
NCT07326488MHB009CPhase 1Advanced Malignant Solid TumorOncologyFeb 2028
NCT07682506MH004 1.0% OintmentPhase 3VitiligoImmunologyFeb 2028
NCT06345482MHB039A for InjectionPhase 1Advanced Solid TumorOncologyApr 2028
NCT07622108MHB018APhase 3Thyroid Eye Disease, TEDOphthalmologyJul 2028
NCT07622121MHB018APhase 3Thyroid Eye Disease, TEDOphthalmologyJul 2028
NCT07262476MHB018APhase 3Thyroid Eye Disease (TED)OphthalmologyJan 2029
NCT07045454MHB118C for InjectionPhase 1Advanced Malignant Solid TumorOncologyMar 2029
NCT07229599MHB036C for InjectionPhase 1Advanced Lung CancerOncologyMay 2029
NCT07229599MHB039A for InjectionPhase 1Advanced Lung CancerOncologyMay 2029
NCT06985355MHB046CPhase 1Advanced Solid CancerOncologyMay 2029
NCT07130383MHB036C for InjectionPhase 2Advanced Breast CancerOncologyAug 2029
NCT07130383MHB039A for InjectionPhase 2Advanced Breast CancerOncologyAug 2029
NCT07126665MHB039A for InjectionPhase 1Advanced Malignant Solid TumorOncologyAug 2029
NCT07126665MHB088CPhase 1Advanced Malignant Solid TumorOncologyAug 2029
NCT07192120MHB048CPhase 1mCRPC (Metastatic Castration-resistant Prostate Cancer)OncologyOct 2029
NCT07192107MHB042CPhase 1Advanced Malignant Solid TumorOncologyOct 2029

Targets

IGF1R (1)

Companies with the same targets

Innovent Biologics (Suzhou) OHB Neonatology Amgen Candid Therapeutics Viridian Therapeutics Sling Therapeutics Zai Lab (Shanghai)

Companies built like this

Zai Lab (Shanghai) Philogen Kyowa Kirin Stemline Therapeutics Shandong Boan Biotechnology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.